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Rheumatoid arthritis (RA) and osteoarthritis (OA) cause 
enormous patient suﬀ  ering and economic burden. Due to 
non-steroidal anti-inﬂ   ammatory drug (NSAID)- and 
cyclooxygenase-2 (COX-2) inhibitor-associated ulcers 
and cardiovascular adverse events, novel anti-arthritis 
therapies are needed. Natural health product (NHP) use 
by patients to alleviate symptoms is rising globally. 
However, the quality of NHPs is poorly regulated and 
their eﬃ   cacy, toxicity and mechanism(s) of action are not 
understood. Using state-of-the-art approaches, Haqqi 
and colleagues report in Arthritis Research and Th  erapy
[1] that human chondrocytes expressed the p38-mitogen-
activated protein kinase (MAPK) isoforms p38α, -γ and 
-δ, but not p38β. IL-1β enhanced phosphorylation of 
p38α-MAPK and p38γ-MAPK but not of p38δ-MAPK. 
Th  ey showed by gene-silencing that p38-MAPK activa-
tion was mediated by mitogen-activated protein kinase 
kinase 3 (MKK3). A standardized pomegranate extract 
(PE) speciﬁ   cally diminished IL-1-induced and MKK3-
activated p38α-MAPK isoform and Runx2 (runt-related 
transcription factor 2) activity. PE did not interfere with 
the binding of IL-1β to IL-1 receptor, thus ruling out 
steric hindrance as a suppression mechanism. PE also 
inhibited JNK-MAPK and NF-κB activity.
p38, JNK-MAPK and NF-κB pathways are also major 
targets of drug discovery in arthritis. Th  e p38 cascade 
regulates proinﬂ   ammatory genes post-transcriptionally 
but remains a controversial target due to modest eﬃ   cacy 
and severe toxicity in clinical trials [2]. Th  e NF-κB 
pathway regulates cytokine and ADAMTS-4 genes, and is 
an important therapeutic target in arthritis [3]. Activated 
JNK and c-Jun constitute AP-1 factor, which enhances 
synovitis in RA and matrix metalloproteinase (MMP)-
mediated cartilage loss [4]. Runx2 regulates induction of 
collagen II-destroying human MMP-13 and aggrecan-
degrading, ADAMT    S (a disintegrin and metallo  protein-
ase with thrombospondin motifs) genes [5], whose inhi-
bi  tion by PE could potentially reduce cartilage degrada-
tion. Runx2-deﬁ  cient (heterozygous) mice with surgically 
induced knee OA displayed reduced cartilage destruc-
tion, osteophyte formation, type X collagen and MMP-13 
expression (features of OA-associated aberrant hyper-
trophic chondrocyte diﬀ   erentiation) versus wild-type 
mice [6]. Th  us, beneﬁ  cial eﬀ  ects of PE may be through 
these pharmacological targets.
Since the gastrointestinal tract may degrade the active 
ingredients of NHPs, Haqqi and colleagues [7] demon-
strated that oral administration of PE in collagen-induced 
arthritis mouse model protects joints from inﬂ  ammatory 
arthritis. Th  e chondroprotective eﬀ   ects of another PE 
were reconﬁ   rmed in the monoiodoactate-induced OA 
model [8]. Th   ese studies reveal molecular mechanisms of 
PE action, including cartilage-protective active com-
pounds (polyphenols, ellagitannins, quercetin, gallic acid 
and ellagic acid) that work through precise targets [7]. 
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its eﬀ   ectiveness in RA and OA models, identifying 
precise pomegranate active ingredients, their synergistic 
eﬀ  ects and utility for preventing or reducing human OA 
and RA through clinical trials is warranted. Epidemio-
logical studies on non-consuming and pomegranate-
consum  ing populations for incidence of arthritis may 
also be useful. One should also analyze potential 
pharmaco  logical drug-PE interactions.
Th   e anti-arthritic eﬀ  ects of green tea are attributed to 
the multiple activities of non-toxic epigallocatechin-3-
gallate (EGCG). It suppresses IL-1-induced glycosamino-
glycan release from cartilage by inhibiting ADAMTS, 
MMP-1 and MMP-13 expression through preferentially 
blocking NF-κB activity in chondrocytes. EGCG also 
inhibits IL-1-stimulated inducible nitric oxide synthase 
(iNOS), nitric oxide and JNK activities, which mediate 
cartilage degradation. In RA synovial ﬁ  broblasts, EGCG 
inhibits TNF-α-induced MMP-1, MMP-3, ERK (extra-
cellular signal-regulated kinase), p38, JNK and AP-1 
activities. EGCG sensitizes RA ﬁ   broblasts to TNF-α-
induced caspase-3-mediated apoptosis by blocking Akt 
and NF-κB cell survival pathways. EGCG also inhibits 
IL-6 receptor-induced MMP-2, increases gp130 receptor 
in ﬁ   broblasts and ameliorates adjuvant-induced rat 
arthritis. EGCG suppresses osteoclast-speciﬁ  c, NF-ATc1 
and RA-associated bone resorption and ameliorates 
mouse arthritis. It inhibited oncostatin M-stimulated 
CCL2 chemokine expression in human osteoblasts and 
reduced severity of collagen-induced arthritis. Th  ese in 
vitro and in vivo studies suggest that EGCG could reduce 
synovial hyperplasia, cartilage degradation and bone 
resorption by modulating multiple targets in joints [9]. 
Despite its apparent safety in clinical trials of other 
diseases, its potential for causing apoptosis in chondro-
cytes should be tested further.
Resveratrol from grapes displays anti-inﬂ  ammatory 
and chondroprotective activities by increasing proteo-
glycan synthesis and chondrocyte proliferation and by 
suppressing IL-1, reactive oxygen species, p53-induced 
apoptosis, leukotriene B4, prostaglandin E2 synthesis and 
MMPs in vitro [10]. Intra-articular resveratrol treatment 
reduced cartilage loss in rabbit arthritis models. 
Resveratrol induced ﬁ   broblast apoptosis but increased 
chondrocyte survival by activating Sirtuin 1 (a histone 
deacetylase) and Bcl2 [11,12]. Th  us, resveratrol may 
prevent intervertebral disc degeneration, OA-associated 
inﬂ   ammation, chondrocyte apoptosis, and RA-related 
pannus formation, desirable goals in treating OA and RA. 
Resveratrol-like Sirtuin 1 activators are also being 
developed as lifespan-extending drugs.
Curcumin suppresses inﬂ   ammatory and catabolic 
mediators such as IL-1β-stimulated nitric oxide, prosta-
glandin E2, COX-2, IL-6, IL-8, MMP-3, MMP-9, JNK and 
NF-κB activation and the oncostatin M-induced JAK/
STAT pathway in human chondrocytes [13]. It promotes 
chondrogenesis from mesenchymal stem cells by antago-
nizing proinﬂ   ammatory cytokines [14]. Despite these 
anti-inﬂ  ammatory, antioxidant, anti-angiogenic activities, 
its oral consumption and tissue bioavailability are 
problem  atic. Other NHPs, quercetin, triptolide and 
silymarin, target inﬂ  ammatory cytokines, NF-κB, COX-2 
and catabolic MMPs [15].
It is laudable that regulatory agencies are encouraging 
research to substantiate the therapeutic claims by manu-
facturers of NHPs. We need well-controlled, molecular 
and mechanistic studies on NHPs as modeled by Haqqi 
and colleagues [1]. Currently, we can analyze multiple 
targets of NHPs by gene arrays and proteomics to 
evaluate their eﬃ   cacy in preventing and treating RA and 
OA.
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